Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice

Brain Research

Volumn 1296, Issue , 2009, Pages 148-163

  Uno, Yumiko ^a   Iwashita, Hiroki ^a   Tsukamoto, Tetsuya ^a   Uchiyama, Noriko ^a   Kawamoto, Tomohiro ^a   Kori, Masakuni ^a   Nakanishi, Atsushi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

GSK 3 inhibitor; Tau pathology; Tau phosphorylation; Tauopathy

Indexed keywords

6 METHYL N [3 [[3 (1 METHYLETHOXY)PROPYL]CARBAMOYL] 1H PYRAZOL 4 YL]PYRIDINE 3 CARBOXAMIDE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; IC 50; INHIBITION KINETICS; MALE; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; RAT; TAUOPATHY; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; AGING; ANIMALS; BRAIN; COLD TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; NIACINAMIDE; PHOSPHORYLATION; PROTEIN MULTIMERIZATION; PYRAZOLES; STRESS, PHYSIOLOGICAL; TAU PROTEINS; TIME FACTORS;

MUS; MUS MUSCULUS;

EID: 70349278341     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.08.034     Document Type: Article

References (45)

1. Alonso A.C., Zaidi T., Grundke-Iqbal I., and Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91 (1994) 5562-5566
2. Alonso A.C., Grundke-Iqbal I., and Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2 (1996) 783-787
3. Augustinack J.C., Schneider A., Mandelkow E.M., and Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 103 (2002) 26-35
4. Ballatore C., Lee V.M., and Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev., Neurosci. 8 (2007) 663-672
5. Braak H., and Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991) 239-259
6. Braak H., and Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol. 1 (1991) 213-216
7. Churcher I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 6 (2006) 579-595
8. Cohen P., and Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev., Drug Discov. 3 (2004) 479-489
9. Dickson D.W. Neurodegenerative diseases with cytoskeletal pathology: a biochemical classification. Ann. Neurol. 42 (1997) 541-544
10. Drewes G., Lichtenberg-Kraag B., Doring F., Mandelkow E.M., Biernat J., Goris J., Doree M., and Mandelkow E. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J. 6 (1992) 2131-2138
11. Eckermann K., Mocanu M.M., Khlistunova I., Biernat J., Nissen A., Hofmann A., Schönig K., Bujard H., Haemisch A., Mandelkow E., Zhou L., Rune G., and Mandelkow E.M. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J. Biol. Chem. 282 (2007) 31755-31765
12. Flaherty D.B., Soria J.P., Tomasiewicz H.G., and Wood J.G. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J. Neurosci. Res. 62 (2000) 463-472
13. Engel T., Goñi-Oliver P., Lucas J.J., Avila J., and Hernández F. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 99 (2006) 1445-1455
14. Hernandez F., Borrell J., Guaza C., Avila J., and Lucas J.J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 83 (2002) 1529-1533
15. Ishiguro K., Takamatsu M., Tomizawa K., Omori A., Takahashi M., Arioka M., Uchida T., and Imahori K. Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments. J. Biol. Chem. 267 (1992) 10897-10901
16. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M.K., Trojanowski J.Q., and Lee V.M. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 3 (1999) 751-762
17. Ishihara T., Zhang B., Higuchi M., Yoshiyama Y., Trojanowski J.Q., and Lee V.M. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. Am. J. Pathol. 158 (2001) 555-562
18. Ledesma M.D., Correas I., Avila J., and Diaz-Nido J. Implication of brain cdc2 and MAP2 kinases in the phosphorylation of tau protein in Alzheimer's disease. FEBS Lett. 308 (1992) 218-224
19. Lee V.M., Goedert M., and Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001) 1121-1159
20. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., and Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 4 (2000) 402-405
21. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., and Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20 (2001) 27-39
22. Luna-Muñoz J., García-Sierra F., Falcón V., Menéndez I., Chávez-Macías L., and Mena R. Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease. J. Alzheimer's Dis. 8 (2005) 29-41
23. Mandelkow E.M., Stamer K., Vogel R., Thies E., and Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 8 (2003) 1079-1085
24. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med. Res. Rev. 28 (2008) 773-796
25. Mazanetz M.P., and Fischer P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev., Drug Discov. 6 (2007) 464-479
26. Meijer L., Flajolet M., and Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 9 (2004) 471-480
27. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K., and Ihara Y. Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270 (1995) 823-829
28. Nakashima H., Ishihara T., Suguimoto P., Yokota O., Oshima E., Kugo A., Terada S., Hamamura T., Trojanowski J.Q., Lee V.M., and Kuroda S. Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. 110 (2005) 547-556
29. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., Burns M., Krishnamurthy P., Wen Y., Bhat R., Lewis J., Dickson D., and Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA 102 (2005) 6990-6995
30. Okawa Y., Ishiguro K., and Fujita S.C. Stress-induced hyperphosphorylation of tau in the mouse brain. FEBS Lett. 535 (2003) 183-189
31. Pei J.-J., Tanaka T., Tung Y.-C., Braak E., Iqbal K., and Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56 (1997) 70-78
32. Pei J.-J., Grundke-Iqbal I., Iqbal K., Bogdanovic N., Winblad B., and Cowburn R.F. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797 (1998) 267-277
33. Pei J.-J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., and Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 58 (1999) 1010-1019
34. Pérez M., Hernández F., Lim F., Díaz-Nido J., and Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimer's Dis. 5 (2003) 301-308
35. Sahara N., Vega I.E., Ishizawa T., Lewis J., McGowan E., Hutton M., Dickson D., and Yen S.H. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins. J. Neurochem. 90 (2004) 829-838
36. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B., Hutton, M., Ashe, K.H., 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
37. Selenica M.L., Jensen H.S., Larsen A.K., Pedersen M.L., Helboe L., Leist M., and Lotharius J. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol. 152 (2007) 959-979
38. Sengupta A., Wu Q., Grundke-Iqbal I., Iqbal K., and Singh T.J. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell. Biochem. 167 (1997) 99-105
39. Steinhilb M.L., Dias-Santagata D., Mulkearns E.E., Shulman J.M., Biernat J., Mandelkow E.M., and Feany M.B. S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J. Neurosci. Res. 85 (2007) 1271-1278
40. Steinhilb M.L., Dias-Santagata D., Fulga T.A., Felch D.L., and Feany M.B. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol. Biol. Cell 18 (2007) 5060-5068
41. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., and Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280 (2005) 7614-7623
42. Wagner U., Utton M., Gallo J.M., and Miller C.C. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J. Cell Sci. 109 (1996) 1537-1543
43. Wang J.Z., Grundke-Iqbal I., and Iqbal K. Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Res. Mol. Brain Res. 38 (1996) 200-208
44. Yoshida S., Maeda M., Kaku S., Ikeya H., Yamada K., and Nakaike S. Lithium inhibits stress-induced changes in tau phosphorylation in the mouse hippocampus. J. Neural Transm. 113 (2006) 1803-1814
45. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., and Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53 (2007) 337-351